clinical trial · NCT06929624
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.·phase3·recruiting·n = 280
Diffuse Large B-cell LymphomaSHR-A1912 InjectionRituximab InjectionGemcitabine Hydrochloride for InjectionOxaliplatin Injection
brief summary
This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.
started
Apr 24, 2025
primary completion
Mar 1, 2027
completion
Jan 1, 2028
last updated
Jul 1, 2026
official title
A Phase 3, Open-label, Randomized Study of SHR-A1912 Combined With Rituximab + Gemcitabine + Oxaliplatin (R-GEMOX) Versus R-GEMOX in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol